NDC 85974-131-52

This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.

Requested NDC: 85974-131-52
Product root: 85974-131
Identity scope: Package
Primary current NDC product row: Not present

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 4 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
compounder	package	85974-131	85974-131-52	COMPOUNDER	Outsourcing facility compounded drug report	2026-1	2026-09-18
compounder	package	85974-131	85974-131-52	COMPOUNDER	Outsourcing facility compounded drug report	2025-2	2026-09-18
compounder	package	85974-131	85974-131-52	COMPOUNDER	Outsourcing facility compounded drug report	2025-1	2026-09-18
compounder	package	85974-131	85974-131-52	COMPOUNDER	Outsourcing facility compounded drug report	2025-1	2026-10-06

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 1 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Archive	Snapshot	Source SHA-256
2025-12-16 00:49 UTC · source 2025-09-25	compounder	package	85974-131	85974-131-52	COMPOUNDER	Outsourcing facility compounded drug report		compounder / compounders_ndc_directory.zip	`3f6f48d8db7b…`	`6316a3eebc6a…`

Compounder NDC reports#

Browse the complete compounder directory for this NDC · Browse every current compounder row in the unified auxiliary catalog · browse compounder source captures and parsed snapshots.

Establishment, FEI, Product NDC table
Establishment	Product NDC	Package NDC	Product	Active ingredients	Reporting period	Normalization
Bennett Pharmaceuticals of America, LLC	85974-131	85974-131-52	tetracaine hcl 4%, bupivacaine hcl 0.5%, phenylephrine hcl 1% gel	40 mg/1 mL; 5 mg/1 mL; 10 mg/1 mL	2026-1	valid
Bennett Pharmaceuticals of America, LLC	85974-131	85974-131-52	tetracaine hcl 4%, bupivacaine hcl 0.5%, phenylephrine hcl 1% gel	40 mg/1 mL; 5 mg/1 mL; 10 mg/1 mL	2025-2	valid
"Bennett Pharmaceuticals of America, LLC(118622266)"	85974-131	85974-131-52	Tetracaine Hydrochloride; Bupivacaine Hydrochloride; Phenylephrine Hydrochloride	40 mg/1 mL; 5 mg/1 mL; 10 mg/1 mL	2025-1	valid
Bennett Pharmaceuticals of America, LLC	85974-131	85974-131-52	tetracaine hcl 4%, bupivacaine hcl 0.5%, phenylephrine 1% gel	40 mg/1 mL; 5 mg/1 mL; 10 mg/1 mL	2025-1	valid

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.